NEW YORK (GenomeWeb News) — Cepheid and BioMerieux plan to develop and market a line of sepsis tests, the companies said today.
 
The companies said they will develop assays to identify fungi and bacteria and genetic markers for antibiotic resistance. Cepheid and BioMerieux also said that the panel could be used to identify hospital-acquired pneumonia.
 
The tests will work on Cepheid’s GeneXpert platform. Cepheid will manufacture them and BioMerieux will distribute them worldwide.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US Attorney General Jeff Sessions is considering using DNA tests to determine relatedness between adult and child migrants, the Daily Caller reports.

Bloomberg reports that Brainstorm Cell Therapeutics plans to offer a treatment it is developing under the "right to try" law for hundreds of thousands of dollars.

In a proof-of-concept study, researchers report being able to determine age from dried bloodstains, Discover's D-brief blog reports.

In Nature this week: expansion of disease-resistance genes among long-lived oak trees, and more.